Indo Amines Limited
Indo Amines Limited (INDOAMIN.NS) Stock Competitors & Peer Comparison
See (INDOAMIN.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Chemicals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INDOAMIN.NS | ₹113.10 | +0.00% | 8.2B | 11.53 | ₹9.85 | +0.44% |
| UPL.BO | ₹764.35 | +0.00% | 634.6B | 35.93 | ₹20.92 | +0.80% |
| FLUOROCHEM.NS | ₹3,411.40 | +0.00% | 376.3B | 57.34 | ₹59.74 | +0.09% |
| NAVINFLUOR.NS | ₹6,388.00 | +0.00% | 334.4B | 60.44 | ₹107.98 | +0.21% |
| NAVINFLUOR.BO | ₹6,387.25 | +0.00% | 334.4B | 60.42 | ₹108.00 | +0.21% |
| DEEPAKNI.BO | ₹2,436.10 | +0.33% | 332.3B | 57.46 | ₹42.40 | N/A |
| DEEPAKNTR.NS | ₹1,639.80 | +0.00% | 218.8B | 41.10 | ₹39.03 | +0.47% |
| DEEPAKNTR.BO | ₹1,640.80 | +0.00% | 218.8B | 40.99 | ₹39.13 | N/A |
| BAYERCROP.BO | ₹4,767.45 | +0.00% | 215.7B | 32.14 | ₹149.36 | +2.60% |
| TATACHEM.NS | ₹705.10 | +0.00% | 182.4B | 112.77 | ₹6.35 | +1.54% |
Stock Comparison
INDOAMIN.NS vs UPL.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, UPL.BO has a market cap of 634.6B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while UPL.BO trades at ₹764.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas UPL.BO's P/E ratio is 35.93. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to UPL.BO's ROE of +0.05%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to UPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check UPL.BO's competition here
INDOAMIN.NS vs FLUOROCHEM.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, FLUOROCHEM.NS has a market cap of 376.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while FLUOROCHEM.NS trades at ₹3,411.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas FLUOROCHEM.NS's P/E ratio is 57.34. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to FLUOROCHEM.NS's ROE of +0.09%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to FLUOROCHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check FLUOROCHEM.NS's competition here
INDOAMIN.NS vs NAVINFLUOR.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, NAVINFLUOR.NS has a market cap of 334.4B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while NAVINFLUOR.NS trades at ₹6,388.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas NAVINFLUOR.NS's P/E ratio is 60.44. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to NAVINFLUOR.NS's ROE of +0.19%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to NAVINFLUOR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check NAVINFLUOR.NS's competition here
INDOAMIN.NS vs NAVINFLUOR.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, NAVINFLUOR.BO has a market cap of 334.4B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while NAVINFLUOR.BO trades at ₹6,387.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas NAVINFLUOR.BO's P/E ratio is 60.42. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to NAVINFLUOR.BO's ROE of +0.19%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to NAVINFLUOR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check NAVINFLUOR.BO's competition here
INDOAMIN.NS vs DEEPAKNI.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DEEPAKNI.BO has a market cap of 332.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DEEPAKNI.BO trades at ₹2,436.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DEEPAKNI.BO's P/E ratio is 57.46. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DEEPAKNI.BO's ROE of +0.06%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to DEEPAKNI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DEEPAKNI.BO's competition here
INDOAMIN.NS vs DEEPAKNTR.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DEEPAKNTR.NS has a market cap of 218.8B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DEEPAKNTR.NS trades at ₹1,639.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DEEPAKNTR.NS's P/E ratio is 41.10. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DEEPAKNTR.NS's ROE of +0.10%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to DEEPAKNTR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DEEPAKNTR.NS's competition here
INDOAMIN.NS vs DEEPAKNTR.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DEEPAKNTR.BO has a market cap of 218.8B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DEEPAKNTR.BO trades at ₹1,640.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DEEPAKNTR.BO's P/E ratio is 40.99. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DEEPAKNTR.BO's ROE of +0.06%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to DEEPAKNTR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DEEPAKNTR.BO's competition here
INDOAMIN.NS vs BAYERCROP.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, BAYERCROP.BO has a market cap of 215.7B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while BAYERCROP.BO trades at ₹4,767.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas BAYERCROP.BO's P/E ratio is 32.14. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to BAYERCROP.BO's ROE of +0.23%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to BAYERCROP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check BAYERCROP.BO's competition here
INDOAMIN.NS vs TATACHEM.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, TATACHEM.NS has a market cap of 182.4B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while TATACHEM.NS trades at ₹705.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas TATACHEM.NS's P/E ratio is 112.77. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to TATACHEM.NS's ROE of +0.01%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to TATACHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check TATACHEM.NS's competition here
INDOAMIN.NS vs TATACHEM.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, TATACHEM.BO has a market cap of 182.2B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while TATACHEM.BO trades at ₹705.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas TATACHEM.BO's P/E ratio is 111.94. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to TATACHEM.BO's ROE of +0.01%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to TATACHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check TATACHEM.BO's competition here
INDOAMIN.NS vs DEEPAKFERT.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DEEPAKFERT.NS has a market cap of 126.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DEEPAKFERT.NS trades at ₹1,003.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DEEPAKFERT.NS's P/E ratio is 14.44. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DEEPAKFERT.NS's ROE of +0.14%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to DEEPAKFERT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DEEPAKFERT.NS's competition here
INDOAMIN.NS vs DEEPAKFERT.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DEEPAKFERT.BO has a market cap of 126.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DEEPAKFERT.BO trades at ₹1,004.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DEEPAKFERT.BO's P/E ratio is 14.44. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DEEPAKFERT.BO's ROE of +0.14%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to DEEPAKFERT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DEEPAKFERT.BO's competition here
INDOAMIN.NS vs SPLPETRO.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, SPLPETRO.NS has a market cap of 124.5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while SPLPETRO.NS trades at ₹650.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas SPLPETRO.NS's P/E ratio is 45.62. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to SPLPETRO.NS's ROE of +0.12%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to SPLPETRO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check SPLPETRO.NS's competition here
INDOAMIN.NS vs ACI.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, ACI.BO has a market cap of 69.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while ACI.BO trades at ₹566.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas ACI.BO's P/E ratio is 47.43. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to ACI.BO's ROE of +0.08%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to ACI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check ACI.BO's competition here
INDOAMIN.NS vs ACI.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, ACI.NS has a market cap of 69.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while ACI.NS trades at ₹566.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas ACI.NS's P/E ratio is 47.04. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to ACI.NS's ROE of +0.08%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to ACI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check ACI.NS's competition here
INDOAMIN.NS vs GNFC.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, GNFC.NS has a market cap of 68.2B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while GNFC.NS trades at ₹461.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas GNFC.NS's P/E ratio is 10.94. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to GNFC.NS's ROE of +0.07%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to GNFC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check GNFC.NS's competition here
INDOAMIN.NS vs GNFC.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, GNFC.BO has a market cap of 68.2B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while GNFC.BO trades at ₹460.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas GNFC.BO's P/E ratio is 10.71. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to GNFC.BO's ROE of +0.07%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to GNFC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check GNFC.BO's competition here
INDOAMIN.NS vs INDIAGLYCO.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, INDIAGLYCO.BO has a market cap of 63.5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while INDIAGLYCO.BO trades at ₹945.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas INDIAGLYCO.BO's P/E ratio is 22.62. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to INDIAGLYCO.BO's ROE of +0.12%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to INDIAGLYCO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check INDIAGLYCO.BO's competition here
INDOAMIN.NS vs INDIAGLYCO.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, INDIAGLYCO.NS has a market cap of 63.4B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while INDIAGLYCO.NS trades at ₹941.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas INDIAGLYCO.NS's P/E ratio is 21.92. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to INDIAGLYCO.NS's ROE of +0.12%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to INDIAGLYCO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check INDIAGLYCO.NS's competition here
INDOAMIN.NS vs RAIN.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, RAIN.BO has a market cap of 49B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while RAIN.BO trades at ₹147.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas RAIN.BO's P/E ratio is -37.06. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to RAIN.BO's ROE of -0.02%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to RAIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check RAIN.BO's competition here
INDOAMIN.NS vs RAIN.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, RAIN.NS has a market cap of 48.9B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while RAIN.NS trades at ₹147.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas RAIN.NS's P/E ratio is -36.94. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to RAIN.NS's ROE of -0.02%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to RAIN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check RAIN.NS's competition here
INDOAMIN.NS vs GHCL.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, GHCL.BO has a market cap of 45.7B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while GHCL.BO trades at ₹498.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas GHCL.BO's P/E ratio is 9.35. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to GHCL.BO's ROE of +0.15%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to GHCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check GHCL.BO's competition here
INDOAMIN.NS vs GHCL.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, GHCL.NS has a market cap of 45.7B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while GHCL.NS trades at ₹499.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas GHCL.NS's P/E ratio is 9.34. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to GHCL.NS's ROE of +0.15%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to GHCL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check GHCL.NS's competition here
INDOAMIN.NS vs CHEMPLASTS.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, CHEMPLASTS.NS has a market cap of 45.6B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while CHEMPLASTS.NS trades at ₹289.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas CHEMPLASTS.NS's P/E ratio is -15.96. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to CHEMPLASTS.NS's ROE of -0.15%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to CHEMPLASTS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check CHEMPLASTS.NS's competition here
INDOAMIN.NS vs CHEMPLASTS.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, CHEMPLASTS.BO has a market cap of 45.6B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while CHEMPLASTS.BO trades at ₹289.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas CHEMPLASTS.BO's P/E ratio is -15.98. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to CHEMPLASTS.BO's ROE of -0.15%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to CHEMPLASTS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check CHEMPLASTS.BO's competition here
INDOAMIN.NS vs MFL.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, MFL.NS has a market cap of 44.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while MFL.NS trades at ₹1,062.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas MFL.NS's P/E ratio is 15.94. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to MFL.NS's ROE of +0.39%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to MFL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check MFL.NS's competition here
INDOAMIN.NS vs EPIGRAL.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, EPIGRAL.NS has a market cap of 40.6B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while EPIGRAL.NS trades at ₹979.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas EPIGRAL.NS's P/E ratio is 12.00. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to EPIGRAL.NS's ROE of +0.18%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to EPIGRAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check EPIGRAL.NS's competition here
INDOAMIN.NS vs EPIGRAL.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, EPIGRAL.BO has a market cap of 40.6B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while EPIGRAL.BO trades at ₹981.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas EPIGRAL.BO's P/E ratio is 12.00. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to EPIGRAL.BO's ROE of +0.18%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to EPIGRAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check EPIGRAL.BO's competition here
INDOAMIN.NS vs MEGH.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, MEGH.NS has a market cap of 35.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while MEGH.NS trades at ₹139.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas MEGH.NS's P/E ratio is 15.63. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to MEGH.NS's ROE of +0.16%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to MEGH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check MEGH.NS's competition here
INDOAMIN.NS vs STYRENIX.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, STYRENIX.NS has a market cap of 34.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while STYRENIX.NS trades at ₹1,972.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas STYRENIX.NS's P/E ratio is 20.69. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to STYRENIX.NS's ROE of +0.14%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to STYRENIX.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check STYRENIX.NS's competition here
INDOAMIN.NS vs STYRENIX.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, STYRENIX.BO has a market cap of 34.2B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while STYRENIX.BO trades at ₹1,972.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas STYRENIX.BO's P/E ratio is 20.69. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to STYRENIX.BO's ROE of +0.14%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to STYRENIX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check STYRENIX.BO's competition here
INDOAMIN.NS vs GUJALKALI.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, GUJALKALI.BO has a market cap of 34.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while GUJALKALI.BO trades at ₹468.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas GUJALKALI.BO's P/E ratio is -404.09. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to GUJALKALI.BO's ROE of -0.00%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to GUJALKALI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check GUJALKALI.BO's competition here
INDOAMIN.NS vs GUJALKALI.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, GUJALKALI.NS has a market cap of 34.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while GUJALKALI.NS trades at ₹467.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas GUJALKALI.NS's P/E ratio is -403.91. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to GUJALKALI.NS's ROE of -0.00%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to GUJALKALI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check GUJALKALI.NS's competition here
INDOAMIN.NS vs ELLEN.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, ELLEN.NS has a market cap of 34.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while ELLEN.NS trades at ₹245.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas ELLEN.NS's P/E ratio is N/A. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to ELLEN.NS's ROE of +0.12%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to ELLEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check ELLEN.NS's competition here
INDOAMIN.NS vs RPEL.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, RPEL.BO has a market cap of 31.5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while RPEL.BO trades at ₹699.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas RPEL.BO's P/E ratio is 63.48. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to RPEL.BO's ROE of +0.26%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to RPEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check RPEL.BO's competition here
INDOAMIN.NS vs RPEL.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, RPEL.NS has a market cap of 31.5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while RPEL.NS trades at ₹699.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas RPEL.NS's P/E ratio is 64.88. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to RPEL.NS's ROE of +0.24%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to RPEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check RPEL.NS's competition here
INDOAMIN.NS vs FOSECOIND.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, FOSECOIND.BO has a market cap of 30.4B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while FOSECOIND.BO trades at ₹4,601.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas FOSECOIND.BO's P/E ratio is 38.39. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to FOSECOIND.BO's ROE of +0.23%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to FOSECOIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check FOSECOIND.BO's competition here
INDOAMIN.NS vs FOSECOIND.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, FOSECOIND.NS has a market cap of 30.2B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while FOSECOIND.NS trades at ₹4,601.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas FOSECOIND.NS's P/E ratio is 38.07. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to FOSECOIND.NS's ROE of +0.23%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to FOSECOIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check FOSECOIND.NS's competition here
INDOAMIN.NS vs DDEVPLASTIK.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DDEVPLASTIK.BO has a market cap of 27.2B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DDEVPLASTIK.BO trades at ₹262.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DDEVPLASTIK.BO's P/E ratio is 14.39. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DDEVPLASTIK.BO's ROE of +0.24%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to DDEVPLASTIK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DDEVPLASTIK.BO's competition here
INDOAMIN.NS vs BEPL.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, BEPL.NS has a market cap of 20.8B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while BEPL.NS trades at ₹84.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas BEPL.NS's P/E ratio is 12.51. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to BEPL.NS's ROE of +0.17%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to BEPL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check BEPL.NS's competition here
INDOAMIN.NS vs BEPL.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, BEPL.BO has a market cap of 20.8B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while BEPL.BO trades at ₹84.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas BEPL.BO's P/E ratio is 12.47. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to BEPL.BO's ROE of +0.17%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to BEPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check BEPL.BO's competition here
INDOAMIN.NS vs SANSTAR.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, SANSTAR.NS has a market cap of 16B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while SANSTAR.NS trades at ₹88.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas SANSTAR.NS's P/E ratio is 82.12. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to SANSTAR.NS's ROE of +0.03%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to SANSTAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check SANSTAR.NS's competition here
INDOAMIN.NS vs DCW.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DCW.BO has a market cap of 14.9B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DCW.BO trades at ₹50.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DCW.BO's P/E ratio is 29.82. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DCW.BO's ROE of +0.04%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to DCW.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DCW.BO's competition here
INDOAMIN.NS vs DCW.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DCW.NS has a market cap of 14.9B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DCW.NS trades at ₹50.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DCW.NS's P/E ratio is 35.73. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DCW.NS's ROE of +0.04%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to DCW.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DCW.NS's competition here
INDOAMIN.NS vs GODAVARIB.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, GODAVARIB.NS has a market cap of 14.8B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while GODAVARIB.NS trades at ₹277.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas GODAVARIB.NS's P/E ratio is 73.59. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to GODAVARIB.NS's ROE of +0.03%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to GODAVARIB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check GODAVARIB.NS's competition here
INDOAMIN.NS vs INEOSSTYRO.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, INEOSSTYRO.NS has a market cap of 14.2B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while INEOSSTYRO.NS trades at ₹807.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas INEOSSTYRO.NS's P/E ratio is 11.53. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to INEOSSTYRO.NS's ROE of +0.23%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to INEOSSTYRO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check INEOSSTYRO.NS's competition here
INDOAMIN.NS vs PUNJABCHEM.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, PUNJABCHEM.NS has a market cap of 12.6B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while PUNJABCHEM.NS trades at ₹1,022.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas PUNJABCHEM.NS's P/E ratio is 20.90. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to PUNJABCHEM.NS's ROE of +0.16%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to PUNJABCHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check PUNJABCHEM.NS's competition here
INDOAMIN.NS vs PUNJABCHEM.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, PUNJABCHEM.BO has a market cap of 12.5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while PUNJABCHEM.BO trades at ₹1,017.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas PUNJABCHEM.BO's P/E ratio is 20.86. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to PUNJABCHEM.BO's ROE of +0.16%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to PUNJABCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check PUNJABCHEM.BO's competition here
INDOAMIN.NS vs IGPL.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, IGPL.BO has a market cap of 11.4B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while IGPL.BO trades at ₹364.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas IGPL.BO's P/E ratio is 34.98. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to IGPL.BO's ROE of -0.01%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to IGPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check IGPL.BO's competition here
INDOAMIN.NS vs A1L.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, A1L.BO has a market cap of 11.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while A1L.BO trades at ₹25.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas A1L.BO's P/E ratio is 302.38. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to A1L.BO's ROE of +0.03%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to A1L.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check A1L.BO's competition here
INDOAMIN.NS vs GEMAROMA.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, GEMAROMA.NS has a market cap of 10.2B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while GEMAROMA.NS trades at ₹193.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas GEMAROMA.NS's P/E ratio is 36.33. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to GEMAROMA.NS's ROE of +0.08%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to GEMAROMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check GEMAROMA.NS's competition here
INDOAMIN.NS vs ANDHRSUGAR.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, ANDHRSUGAR.NS has a market cap of 9.8B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while ANDHRSUGAR.NS trades at ₹72.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas ANDHRSUGAR.NS's P/E ratio is 11.69. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to ANDHRSUGAR.NS's ROE of +0.05%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to ANDHRSUGAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check ANDHRSUGAR.NS's competition here
INDOAMIN.NS vs ZUARI.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, ZUARI.BO has a market cap of 9.7B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while ZUARI.BO trades at ₹232.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas ZUARI.BO's P/E ratio is 1.01. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to ZUARI.BO's ROE of +0.41%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to ZUARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check ZUARI.BO's competition here
INDOAMIN.NS vs ANDHRSUGAR.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, ANDHRSUGAR.BO has a market cap of 9.7B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while ANDHRSUGAR.BO trades at ₹72.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas ANDHRSUGAR.BO's P/E ratio is 11.63. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to ANDHRSUGAR.BO's ROE of +0.05%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to ANDHRSUGAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check ANDHRSUGAR.BO's competition here
INDOAMIN.NS vs GULPOLY.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, GULPOLY.NS has a market cap of 9.6B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while GULPOLY.NS trades at ₹154.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas GULPOLY.NS's P/E ratio is 12.49. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to GULPOLY.NS's ROE of +0.12%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to GULPOLY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check GULPOLY.NS's competition here
INDOAMIN.NS vs GULPOLY.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, GULPOLY.BO has a market cap of 9.5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while GULPOLY.BO trades at ₹154.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas GULPOLY.BO's P/E ratio is 12.50. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to GULPOLY.BO's ROE of +0.12%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to GULPOLY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check GULPOLY.BO's competition here
INDOAMIN.NS vs AMNPLST.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, AMNPLST.BO has a market cap of 9.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while AMNPLST.BO trades at ₹165.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas AMNPLST.BO's P/E ratio is 25.16. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to AMNPLST.BO's ROE of +0.13%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to AMNPLST.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check AMNPLST.BO's competition here
INDOAMIN.NS vs AMNPLST.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, AMNPLST.NS has a market cap of 9B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while AMNPLST.NS trades at ₹163.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas AMNPLST.NS's P/E ratio is 25.04. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to AMNPLST.NS's ROE of +0.13%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to AMNPLST.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check AMNPLST.NS's competition here
INDOAMIN.NS vs SRHHYPOLTD.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, SRHHYPOLTD.BO has a market cap of 8.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while SRHHYPOLTD.BO trades at ₹489.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas SRHHYPOLTD.BO's P/E ratio is 9.03. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to SRHHYPOLTD.BO's ROE of +0.10%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to SRHHYPOLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check SRHHYPOLTD.BO's competition here
INDOAMIN.NS vs SRHHYPOLTD.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, SRHHYPOLTD.NS has a market cap of 8.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while SRHHYPOLTD.NS trades at ₹490.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas SRHHYPOLTD.NS's P/E ratio is 8.94. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to SRHHYPOLTD.NS's ROE of +0.10%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to SRHHYPOLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check SRHHYPOLTD.NS's competition here
INDOAMIN.NS vs INDOAMIN.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, INDOAMIN.BO has a market cap of 8.2B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while INDOAMIN.BO trades at ₹113.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas INDOAMIN.BO's P/E ratio is 11.44. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to INDOAMIN.BO's ROE of +0.22%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to INDOAMIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check INDOAMIN.BO's competition here
INDOAMIN.NS vs ORIENTCQ.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, ORIENTCQ.BO has a market cap of 8.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while ORIENTCQ.BO trades at ₹810.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas ORIENTCQ.BO's P/E ratio is 15.88. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to ORIENTCQ.BO's ROE of +0.01%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to ORIENTCQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check ORIENTCQ.BO's competition here
INDOAMIN.NS vs INDOBORAX.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, INDOBORAX.NS has a market cap of 7.9B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while INDOBORAX.NS trades at ₹247.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas INDOBORAX.NS's P/E ratio is 17.10. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to INDOBORAX.NS's ROE of +0.14%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to INDOBORAX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check INDOBORAX.NS's competition here
INDOAMIN.NS vs INDOBORAX.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, INDOBORAX.BO has a market cap of 7.9B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while INDOBORAX.BO trades at ₹248.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas INDOBORAX.BO's P/E ratio is 17.10. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to INDOBORAX.BO's ROE of +0.14%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to INDOBORAX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check INDOBORAX.BO's competition here
INDOAMIN.NS vs UNIENTER.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, UNIENTER.NS has a market cap of 7.5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while UNIENTER.NS trades at ₹109.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas UNIENTER.NS's P/E ratio is 38.03. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to UNIENTER.NS's ROE of +0.01%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to UNIENTER.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check UNIENTER.NS's competition here
INDOAMIN.NS vs VALIANTORG.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, VALIANTORG.NS has a market cap of 6.9B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while VALIANTORG.NS trades at ₹242.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas VALIANTORG.NS's P/E ratio is 29.53. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to VALIANTORG.NS's ROE of +0.03%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to VALIANTORG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check VALIANTORG.NS's competition here
INDOAMIN.NS vs VALIANTORG.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, VALIANTORG.BO has a market cap of 6.9B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while VALIANTORG.BO trades at ₹242.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas VALIANTORG.BO's P/E ratio is 29.39. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to VALIANTORG.BO's ROE of +0.03%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to VALIANTORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check VALIANTORG.BO's competition here
INDOAMIN.NS vs SUNSHIEL.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, SUNSHIEL.BO has a market cap of 6.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while SUNSHIEL.BO trades at ₹855.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas SUNSHIEL.BO's P/E ratio is 25.79. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to SUNSHIEL.BO's ROE of +0.25%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to SUNSHIEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check SUNSHIEL.BO's competition here
INDOAMIN.NS vs DMCC.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DMCC.BO has a market cap of 6.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DMCC.BO trades at ₹239.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DMCC.BO's P/E ratio is 23.16. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DMCC.BO's ROE of +0.12%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to DMCC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DMCC.BO's competition here
INDOAMIN.NS vs DMCC.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DMCC.NS has a market cap of 6.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DMCC.NS trades at ₹241.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DMCC.NS's P/E ratio is 23.06. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DMCC.NS's ROE of +0.12%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to DMCC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DMCC.NS's competition here
INDOAMIN.NS vs NATPEROX.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, NATPEROX.BO has a market cap of 6B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while NATPEROX.BO trades at ₹1,040.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas NATPEROX.BO's P/E ratio is 399.75. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to NATPEROX.BO's ROE of -0.02%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to NATPEROX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check NATPEROX.BO's competition here
INDOAMIN.NS vs PRIMO.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, PRIMO.NS has a market cap of 5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while PRIMO.NS trades at ₹20.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas PRIMO.NS's P/E ratio is 64.91. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to PRIMO.NS's ROE of +0.02%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to PRIMO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check PRIMO.NS's competition here
INDOAMIN.NS vs SHIVALIK.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, SHIVALIK.BO has a market cap of 4.7B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while SHIVALIK.BO trades at ₹297.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas SHIVALIK.BO's P/E ratio is 33.81. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to SHIVALIK.BO's ROE of +0.02%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to SHIVALIK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check SHIVALIK.BO's competition here
INDOAMIN.NS vs OCCLLTD.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, OCCLLTD.NS has a market cap of 4.6B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while OCCLLTD.NS trades at ₹90.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas OCCLLTD.NS's P/E ratio is 12.31. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to OCCLLTD.NS's ROE of +0.09%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to OCCLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check OCCLLTD.NS's competition here
INDOAMIN.NS vs ARIES.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, ARIES.BO has a market cap of 4.5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while ARIES.BO trades at ₹346.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas ARIES.BO's P/E ratio is 11.76. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to ARIES.BO's ROE of +0.15%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to ARIES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check ARIES.BO's competition here
INDOAMIN.NS vs NAPEROL.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, NAPEROL.BO has a market cap of 3.7B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while NAPEROL.BO trades at ₹629.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas NAPEROL.BO's P/E ratio is 39.54. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to NAPEROL.BO's ROE of -0.02%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to NAPEROL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check NAPEROL.BO's competition here
INDOAMIN.NS vs KANORICHEM.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, KANORICHEM.BO has a market cap of 3.4B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while KANORICHEM.BO trades at ₹77.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas KANORICHEM.BO's P/E ratio is -4.98. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to KANORICHEM.BO's ROE of -0.08%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to KANORICHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check KANORICHEM.BO's competition here
INDOAMIN.NS vs KANORICHEM.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, KANORICHEM.NS has a market cap of 3.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while KANORICHEM.NS trades at ₹75.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas KANORICHEM.NS's P/E ratio is -4.82. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to KANORICHEM.NS's ROE of -0.08%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to KANORICHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check KANORICHEM.NS's competition here
INDOAMIN.NS vs LORDSCHLO.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, LORDSCHLO.NS has a market cap of 3.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while LORDSCHLO.NS trades at ₹126.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas LORDSCHLO.NS's P/E ratio is 12.21. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to LORDSCHLO.NS's ROE of +0.14%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to LORDSCHLO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check LORDSCHLO.NS's competition here
INDOAMIN.NS vs DCMSRMIND.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DCMSRMIND.BO has a market cap of 3.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DCMSRMIND.BO trades at ₹175.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DCMSRMIND.BO's P/E ratio is 3.63. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DCMSRMIND.BO's ROE of +0.05%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to DCMSRMIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DCMSRMIND.BO's competition here
INDOAMIN.NS vs LORDSCHLO.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, LORDSCHLO.BO has a market cap of 3.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while LORDSCHLO.BO trades at ₹126.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas LORDSCHLO.BO's P/E ratio is 12.15. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to LORDSCHLO.BO's ROE of +0.14%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to LORDSCHLO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check LORDSCHLO.BO's competition here
INDOAMIN.NS vs INDGELA.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, INDGELA.BO has a market cap of 2.5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while INDGELA.BO trades at ₹345.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas INDGELA.BO's P/E ratio is 9.40. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to INDGELA.BO's ROE of +0.15%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to INDGELA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check INDGELA.BO's competition here
INDOAMIN.NS vs OCCL.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, OCCL.NS has a market cap of 2.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while OCCL.NS trades at ₹233.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas OCCL.NS's P/E ratio is 77.52. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to OCCL.NS's ROE of +0.02%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to OCCL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check OCCL.NS's competition here
INDOAMIN.NS vs DIAMINESQ.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DIAMINESQ.NS has a market cap of 2.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DIAMINESQ.NS trades at ₹238.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DIAMINESQ.NS's P/E ratio is -46.23. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DIAMINESQ.NS's ROE of -0.06%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to DIAMINESQ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DIAMINESQ.NS's competition here
INDOAMIN.NS vs DIAMINESQ.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DIAMINESQ.BO has a market cap of 2.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DIAMINESQ.BO trades at ₹238.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DIAMINESQ.BO's P/E ratio is -45.77. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DIAMINESQ.BO's ROE of -0.06%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to DIAMINESQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DIAMINESQ.BO's competition here
INDOAMIN.NS vs JAYSYNTH.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, JAYSYNTH.BO has a market cap of 1.7B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while JAYSYNTH.BO trades at ₹12.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas JAYSYNTH.BO's P/E ratio is 14.18. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to JAYSYNTH.BO's ROE of N/A. Regarding short-term risk, INDOAMIN.NS is less volatile compared to JAYSYNTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check JAYSYNTH.BO's competition here
INDOAMIN.NS vs ISHANCH.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, ISHANCH.NS has a market cap of 1.6B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while ISHANCH.NS trades at ₹60.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas ISHANCH.NS's P/E ratio is -29.82. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to ISHANCH.NS's ROE of -0.08%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to ISHANCH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check ISHANCH.NS's competition here
INDOAMIN.NS vs PAUSHAKLTD.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, PAUSHAKLTD.BO has a market cap of 1.5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while PAUSHAKLTD.BO trades at ₹517.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas PAUSHAKLTD.BO's P/E ratio is 33.98. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to PAUSHAKLTD.BO's ROE of +0.08%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to PAUSHAKLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check PAUSHAKLTD.BO's competition here
INDOAMIN.NS vs CHEMCRUX.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, CHEMCRUX.BO has a market cap of 1.5B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while CHEMCRUX.BO trades at ₹101.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas CHEMCRUX.BO's P/E ratio is 70.41. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to CHEMCRUX.BO's ROE of +0.03%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to CHEMCRUX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check CHEMCRUX.BO's competition here
INDOAMIN.NS vs RESGEN.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, RESGEN.BO has a market cap of 1.3B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while RESGEN.BO trades at ₹60.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas RESGEN.BO's P/E ratio is 15.45. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to RESGEN.BO's ROE of +0.14%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to RESGEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check RESGEN.BO's competition here
INDOAMIN.NS vs DEEPAKCHEM.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, DEEPAKCHEM.BO has a market cap of 1.1B. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while DEEPAKCHEM.BO trades at ₹101.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas DEEPAKCHEM.BO's P/E ratio is 10.18. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to DEEPAKCHEM.BO's ROE of +0.19%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to DEEPAKCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check DEEPAKCHEM.BO's competition here
INDOAMIN.NS vs POLYCHEM.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, POLYCHEM.BO has a market cap of 796M. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while POLYCHEM.BO trades at ₹1,979.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas POLYCHEM.BO's P/E ratio is 4.26. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to POLYCHEM.BO's ROE of +0.40%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to POLYCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check POLYCHEM.BO's competition here
INDOAMIN.NS vs ASHOKALC.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, ASHOKALC.BO has a market cap of 551.4M. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while ASHOKALC.BO trades at ₹119.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas ASHOKALC.BO's P/E ratio is -10.04. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to ASHOKALC.BO's ROE of +0.05%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to ASHOKALC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check ASHOKALC.BO's competition here
INDOAMIN.NS vs ZR2.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, ZR2.BO has a market cap of 528.9M. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while ZR2.BO trades at ₹140.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas ZR2.BO's P/E ratio is 988.00. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to ZR2.BO's ROE of +0.01%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to ZR2.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check ZR2.BO's competition here
INDOAMIN.NS vs GARODCH.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, GARODCH.BO has a market cap of 482.7M. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while GARODCH.BO trades at ₹138.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas GARODCH.BO's P/E ratio is 2.03. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to GARODCH.BO's ROE of -1.14%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to GARODCH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check GARODCH.BO's competition here
INDOAMIN.NS vs SANGINITA.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, SANGINITA.NS has a market cap of 379.2M. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while SANGINITA.NS trades at ₹14.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas SANGINITA.NS's P/E ratio is -11.18. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to SANGINITA.NS's ROE of -0.06%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to SANGINITA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check SANGINITA.NS's competition here
INDOAMIN.NS vs SHIVAAGRO.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, SHIVAAGRO.BO has a market cap of 352.5M. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while SHIVAAGRO.BO trades at ₹30.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas SHIVAAGRO.BO's P/E ratio is 160.32. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to SHIVAAGRO.BO's ROE of +0.00%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to SHIVAAGRO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check SHIVAAGRO.BO's competition here
INDOAMIN.NS vs CAPRO.BO Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, CAPRO.BO has a market cap of 318.1M. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while CAPRO.BO trades at ₹69.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas CAPRO.BO's P/E ratio is 6916.00. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to CAPRO.BO's ROE of +0.00%. Regarding short-term risk, INDOAMIN.NS is more volatile compared to CAPRO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.NS.Check CAPRO.BO's competition here
INDOAMIN.NS vs VINEETLAB.NS Comparison February 2026
INDOAMIN.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDOAMIN.NS stands at 8.2B. In comparison, VINEETLAB.NS has a market cap of 296.1M. Regarding current trading prices, INDOAMIN.NS is priced at ₹113.10, while VINEETLAB.NS trades at ₹31.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDOAMIN.NS currently has a P/E ratio of 11.53, whereas VINEETLAB.NS's P/E ratio is -2.10. In terms of profitability, INDOAMIN.NS's ROE is +0.22%, compared to VINEETLAB.NS's ROE of -0.60%. Regarding short-term risk, INDOAMIN.NS is less volatile compared to VINEETLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.NS.Check VINEETLAB.NS's competition here